American Heart Journal
Volume 154, Issue 1 , Pages 78.e1-78.e7 , July 2007

Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial

  • Letícia Weiss Ribeiro, MD, MSc

      Affiliations

    • Cardiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
    • ,
  • Jorge P. Ribeiro, MD, ScD

      Affiliations

    • Cardiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
    • ,
  • Ricardo Stein, MD, ScD

      Affiliations

    • Cardiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
    • ,
  • Cristiane Leitão, MD, MSc

      Affiliations

    • Endocrinology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
    • ,
  • Carísi Anne Polanczyk, MD, ScD

      Affiliations

    • Corresponding Author InformationReprint requests: Carísi Anne Polanczyk, MD, ScD, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, sala 2225, 90035-007—Porto Alegre, RS, Brazil
    • Cardiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Received 13 November 2006 ,Accepted 11 April 2007.

References 

  1. Abrams J. Chronic stable angina. N Eng J Med. 2005;352:2524–2533
  2. Haffner SM, Lehto S, Ronnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetics subjects with and without prior history of myocardial infarction. N Eng J Med. 1998;339:229–234
  3. Henry P, Makoswski S, Richard P, et al. Increased incidence of moderate stenosis among patients with diabetes: substrate for myocardial infarction?. Am J Heart. 1997;134:1037–1043
  4. Abaci A, Oguzhan A, Kahraman S, Eryol NK, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999;99:2239–2242
  5. Lemos PA, Hoye A, Serruys W. Recurrent angina after revascularization: an emerging problem for the clinician. Coron Artery Dis. 2004;15(Suppl 1):S11–S15
  6. Alderman EL, Andrews K, Bost J, et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease (BARI). N Eng J Med. 1996;335:217–225
  7. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty or surgery study (MASS II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease. J Am Coll Cardiol. 2004;43:1743–1751
  8. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Eng J Med. 2001;344:1117–1124
  9. Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol. 1998;82:14K–17K
  10. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588
  11. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double blind crossover study. Cardiovasc Drug Ther. 1990;4:853–860
  12. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994;37:279–288
  13. Levy S. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol. 1995;76:12B–16B
  14. Szwed H, Sadowski Z, Elicowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol (TRIMPOL II). Eur Heart J. 2001;22:2267–2274
  15. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003;14:171–179
  16. Szwed H, Sadowski Z, Pachocki R, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL 1. Cardiovasc Drug Ther. 1999;13:217–222
  17. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 Guidelines Update for Exercise Testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation. 2002;106:1883–1892
  18. Crawford MH, Chair FACC, Bernstein SJ, et al. ACC/AHA guidelines for Ambulatory Electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to the Guidelines for Ambulatory Electrocardiography). Circulation. 1999;100:886–893
  19. Perfoff D, Socolow M, Cowan R. The prognostic value of ambulatory blood pressure. JAMA. 1983;249:2792–2798
  20. American Diabetes Association . Clinical Practice Recommendations 2006. Diabetes Care. 2006;29(Suppl 1):S 1–S 85
  21. Desideri A, Celegon L. Metabolic management of ischemic heart disease. Am J Cardiol. 1998;82:50K–53K
  22. Moses JW, Leon MB, Popma JJ. Sirolimus-eluting stents versus standard stents in patients with stenosis in native coronary artery. N Eng J Med. 2003;349:1315–1323
  23. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in angina combination therapy—the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12:35–42
  24. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin. 2004;20:1447–1454
  25. Fragasso M, Piatti PM, Monti L, et al. Short and long beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:1–8
  26. Rodriguez Padial L, Maicas Bellido C, Velazquez Martin M, et al. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease (DIETRIC study). Rev Clin Esp. 2005;205:57–62
  27. Tritto I, Wang P, Kuppusamy P, et al. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol. 2005;46:89–98
  28. Detry JM, Leclercq BS. Trimetazidine European multicenter study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol. 1995;76:8B–11B
  29. Chaitman BR, Stone PH, Knatterud GL, et al. Asymptomatic Cardiac Ischemic Pilot (ACIP) Study: impact of anti-ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. JACC. 1995;26:585–593
  30. Castedo E, Segovia J, Escudero C, et al. Ischemia-reperfusion injury during experimental heart transplantation. Evaluation of trimetazidine cytoprotective effect. Rev Esp Cardiol. 2005;58:941–950

 Dr Ribeiro reports having received consulting and lecture fees and grant support from Laboratórios Servier do Brasil.

PII: S0002-8703(07)00347-X

doi: 10.1016/j.ahj.2007.04.026

American Heart Journal
Volume 154, Issue 1 , Pages 78.e1-78.e7 , July 2007

Article Tools

* Image Usage & Resolution